Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Seminars in Cancer Biology|May 26, 2019
The antigenic link between thyroid autoimmunity and breast cancerIlaria Muller, Peter J Barrett-Lee
Methods in Molecular Medicine|February 24, 2006
Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sectionsBharat Jasani, Anthony Douglas-Jones, Anthony Rhodes, et al.
The Oncologist|June 17, 2010
Effect of patient age on management decisions in breast cancer: consensus from a national consultationRobert C Leonard, Peter J Barrett-Lee, Margot A Gosney, et al.
European Thyroid Journal|September 5, 2017
TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001)Ilaria Muller, Lucy S Kilburn, Peter N Taylor, et al.
Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.
Oncology|February 24, 2006
Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia SurveyPeter J Barrett-Lee, Heinz Ludwig, Gunnar Birgegård, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
The Lancet. Oncology|September 24, 2013
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trialsJoanne S Haviland, J Roger Owen, John A Dewar, et al.
Lancet (London, England)|February 1, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trialJanet A Dunn, Peter Donnelly, Nada Elbeltagi, et al.
The Lancet. Oncology|October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 studyAhmad Awada, Agustin A Garcia, Stephen Chan, et al.
Pageof 2